The short version of dihexa fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-20 and is reviewed periodically as new material appears.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Adenine (symbol A, or Ade) is a purine nucleotide base that is found in DNA, RNA, and ATP. It is usually a white crystalline subtance. The shape of adenine is complementary and pairs to either thymine in DNA or uracil in RNA. In cells, adenine is rare as an independent molecule. It is almost always covalently bound to become a part of a larger biomolecule. Adenine has a central role in cellular respiration. It is part of adenosine triphosphate which provides the energy that drives and supports most activities in living cells, such as protein synthesis, muscle contraction, and nerve impulse propagation. In respiration it also participates as part of the cofactors nicotinamide adenine dinucleotide, flavin adenine dinucleotide, and coenzyme A. It is also part of adenosine, adenosine monophosphate, cyclic adenosine monophosphate, adenosine diphosphate, and S-adenosylmethionine.
The laurel is an evergreen shrub or small tree, variable in size and sometimes reaching 7–18 m (23–59 ft) tall. The genus Laurus includes three accepted species, whose diagnostic key characters often overlap. The bay laurel is dioecious (unisexual), with male and female flowers on separate plants. Each flower is pale yellow-green, about 1 cm (3⁄8 in) diameter, and they are borne in pairs beside a leaf. The leaves are glabrous, 6–12 cm (2–5 in) long and 2–4 cm (3⁄4–1+5⁄8 in) broad, with an entire (untoothed) margin. On some leaves the margin undulates. The fruit is a small, shiny black drupe-like berry about 1 cm (3⁄8 in) long that contains one seed.
Aflatoxins are various poisonous carcinogens and mutagens that are produced by certain molds, especially Aspergillus species such as Aspergillus flavus and Aspergillus parasiticus. According to the USDA, "They are probably the best known and most intensively researched mycotoxins in the world." The fungi grow in soil, decaying vegetation and various staple foodstuffs and commodities such as hay, maize (corn), peanuts, coffee, wheat, millet, sorghum, cassava, rice, chili peppers, cottonseed, tree nuts, sesame seeds, sunflower seeds, and various cereal grains and oil seeds. They have been found in both pet and human foods, as well as in feedstocks for agricultural animals. Animals fed contaminated food can pass aflatoxin transformation products into milk, milk products, and meat. For example, contaminated poultry feed is the suspected source of aflatoxin-contaminated chicken meat and eggs in Pakistan. Children are particularly vulnerable to aflatoxin exposure, which is linked to immune suppression, stunted growth, delayed development, aflatoxicosis, and liver cancer. Some studies have reported an association between childhood stunting and aflatoxin exposure, although this link has not been consistently detected in all studies. Furthermore, a causal relationship between childhood stunting and aflatoxin exposure has yet to be conclusively shown by epidemiological studies, though such investigations are underway. Adults have a higher tolerance to exposure, but are also at risk. No animal species is known to be immune. Aflatoxins are among the most carcinogenic substances known.
Sources: en.wikipedia.org
The ethics of technology is an interdisciplinary subfield of ethics that analyzes technology's ethical implications and explores ways to mitigate potential negative impacts of new technologies. There is a broad range of ethical issues revolving around technology, from specific areas of focus affecting professionals working with technology to broader social, ethical, and legal issues concerning the role of technology in society and everyday life. Prominent debates have surrounded genetically modified organisms, the use of military robots, algorithmic bias, and the issue of aligning AI behavior with human values. Technology ethics encompasses several key fields: Bioethics looks at ethical issues surrounding biotechnologies and modern medicine, including cloning, human genetic engineering, and stem cell research. Computer ethics focuses on issues related to computing. Cyberethics explores Internet-related issues like intellectual property rights, privacy, and censorship. Nanoethics examines issues surrounding the alteration of matter at the atomic and molecular level in various disciplines, including computer science, engineering, and biology. And engineering ethics deals with the professional standards of engineers, including software engineers and their moral responsibilities to the public.
North Carolina State University's College of Veterinary Medicine in Raleigh, North Carolina, uses both plastic coating (PC) and plastination (PN) to investigate and compare the difference in the two methods. The PC method was simple and inexpensive, but the PN specimens were more flexible, durable, and lifelike than those preserved by the PC method. The use of plastination allowed the use of many body parts such as muscle, nerves, bones, ligaments, and central nervous system to be preserved. The University of Texas Health Science Center at San Antonio was the first school in the United States to use this technique to prepare gross organ specimens for use in teaching. The New York University College of Dentistry, Philadelphia College of Osteopathic Medicine, University of Warwick, and University of Northumbria use collections of plastinates as teaching aids. The University of Vienna and the University of Sheffield have their own plastination laboratories. The first medical school in India to have a plastination lab was A.I.I.M.S, New Delhi with others following suit like Christian Medical College, Vellore, Government Institute of Medical Sciences, Greater Noida etc.
=== EC 2.4.1: Hexosyltransferases === EC 2.4.1.1: Glycogen phosphorylase EC 2.4.1.2: dextrin dextranase EC 2.4.1.3: deleted, included in EC 2.4.1.25 EC 2.4.1.4: amylosucrase EC 2.4.1.5: dextransucrase EC 2.4.1.6: deleted EC 2.4.1.7: sucrose phosphorylase EC 2.4.1.8: maltose phosphorylase EC 2.4.1.9: inulosucrase EC 2.4.1.10: levansucrase EC 2.4.1.11: glycogen(starch) synthase EC 2.4.1.12: cellulose synthase (UDP-forming) EC 2.4.1.13: sucrose synthase EC 2.4.1.14: sucrose-phosphate synthase EC 2.4.1.15: α,α-trehalose-phosphate synthase (UDP-forming) EC 2.4.1.16: chitin synthase EC 2.4.1.17: glucuronosyltransferase EC 2.4.1.18: ,4-α-glucan branching enzyme EC 2.4.1.19: cyclomaltodextrin glucanotransferase EC 2.4.1.20: cellobiose phosphorylase EC 2.4.1.21: starch synthase EC 2.4.1.22: lactose synthase EC 2.4.1.23: sphingosine β-galactosyltransferase EC 2.4.1.24: 1,4-α-glucan 6-α-glucosyltransferase EC 2.4.1.25: 4-α-glucanotransferase EC 2.4.1.26: DNA α-glucosyltransferase EC 2.4.1.27: DNA β-glucosyltransferase EC 2.4.1.28: glucosyl-DNA β-glucosyltransferase EC 2.4.1.29: cellulose synthase (GDP-forming) EC 2.4.1.30: 1,3-β-oligoglucan phosphorylase EC 2.4.1.31: laminaribiose phosphorylase EC 2.4.1.32: glucomannan 4-β-mannosyltransferase EC 2.4.1.33: mannuronan synthase EC 2.4.1.34: 1,3-β-glucan synthase EC 2.4.1.35: phenol β-glucosyltransferase EC 2.4.1.36: α,α-trehalose-phosphate synthase (GDP-forming) EC 2.4.1.37: fucosylgalactoside 3-α-galactosyltransferase EC 2.4.1.38: β-N-acetylglucosaminylglycopeptide β-1,4-galactosyltransferase EC 2.4.1.39: steroid N-acetylglucosaminyltransferase EC 2.4.1.40: glycoprotein-fucosylgalactoside α-N-acetylgalactosaminyltransferase EC 2.4.1.41: polypeptide N-acetylgalactosaminyltransferase EC 2.4.1.42: deleted, included in EC 2.4.1.17 EC 2.4.1.43: polygalacturonate 4-α-galacturonosyltransferase EC 2.4.1.44: lipopolysaccharide 3-α-galactosyltransferase EC 2.4.1.45: now included with EC 2.4.1.47, N-acylsphingosine galactosyltransferase EC 2.4.1.46: monogalactosyldiacylglycerol synthase EC 2.4.1.47: N-acylsphingosine galactosyltransferase EC 2.4.1.48: heteroglycan α-mannosyltransferase EC 2.4.1.49: cellodextrin phosphorylase EC 2.4.1.50: procollagen galactosyltransferase EC 2.4.1.51: now covered by EC 2.4.1.101, EC 2.4.1.143, EC 2.4.1.144 and EC 2.4.1.145 EC 2.4.1.52: poly(glycerol-phosphate) α-glucosyltransferase EC 2.4.1.53: poly(ribitol-phosphate) β-glucosyltransferase EC 2.4.1.54: undecaprenyl-phosphate mannosyltransferase EC 2.4.1.55: Now EC 2.7.8.14, CDP-ribitol ribitolphosphotransferase EC 2.4.1.56: lipopolysaccharide N-acetylglucosaminyltransferase EC 2.4.1.57: Newer studies have shown that this is catalysed by two independent activities now covered by EC 2.4.1.345, phosphatidyl-myo-inositol α-mannosyl transferase and EC 2.4.1.346, phosphatidyl-myo-inositol dimannoside synthase EC 2.4.1.58: lipopolysaccharide glucosyltransferase I EC 2.4.1.59: deleted, included in EC 2.4.1.17 EC 2.4.1.60: CDP-abequose:α-D-Man-(1→4)-α-L-Rha-(1→3)-α-D-Gal-PP-Und α-1,3-abequosyltransferase EC 2.4.1.61: deleted, included in EC 2.4.1.17 EC 2.4.1.62: ganglioside galactosyltransferase EC 2.4.1.63: linamarin synthase EC 2.4.1.64: α,α-trehalose phosphorylase EC 2.4.1.65: 3-galactosyl-N-acetylglucosaminide 4-α-L-fucosyltransferase EC 2.4.1.66: procollagen glucosyltransferase EC 2.4.1.67: galactinol—raffinose galactosyltransferase EC 2.4.1.68: glycoprotein 6-α-L-fucosyltransferase EC 2.4.1.69: type 1 galactoside α-(1,2)-fucosyltransferase EC 2.4.1.70: poly(ribitol-phosphate) α-N-acetylglucosaminyltransferase EC 2.4.1.71: arylamine glucosyltransferase EC 2.4.1.72: now EC 2.4.2.24, 1,4-β-D-xylan synthase EC 2.4.1.73: lipopolysaccharide glucosyltransferase II EC 2.4.1.74: glycosaminoglycan galactosyltransferase EC 2.4.1.75: deleted entry, insufficient evidence to conclude that this is a different enzyme from EC 2.4.1.43 EC 2.4.1.76: deleted, included in EC 2.4.1.17 EC 2.4.1.77: deleted, included in EC 2.4.1.17 EC 2.4.1.78: phosphopolyprenol glucosyltransferase EC 2.4.1.79: globotriaosylceramide 3-β-N-acetylgalactosaminyltransferase EC 2.4.1.80: ceramide glucosyltransferase EC 2.4.1.81: flavone 7-O-β-glucosyltransferase EC 2.4.1.82: galactinol—sucrose galactosyltransferase EC 2.4.1.83: dolichyl-phosphate β-D -mannosyltransferase EC 2.4.1.84: deleted, included in EC 2.4.1.17 EC 2.4.1.85: cyanohydrin β-glucosyltransferase EC 2.4.1.86: N-acetyl-β-D-glucosaminide β-(1,3)-galactosyltransferase EC 2.4.1.87: N-acetyllactosaminide 3-α-galactosyltransferase EC 2.4.1.88: globoside α-N-acetylgalactosaminyltransferase EC 2.4.1.89: deleted, included in EC 2.4.1.69, type 1 galactoside α-(1,2)-fucosyltransferase EC 2.4.1.90: N-acetyllactosamine synthase EC 2.4.1.91: flavonol 3-O-glucosyltransferase EC 2.4.1.92: (N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase EC 2.4.1.93: Now EC 4.2.2.18, inulin fructotransferase (DFA-III-forming) EC 2.4.1.94: protein N-acetylglucosaminyltransferase EC 2.4.1.95: deleted EC 2.4.1.96: sn-glycerol-3-phosphate 1-galactosyltransferase EC 2.4.1.97: 1,3-β-D-glucan phosphorylase EC 2.4.1.98: deleted, Now included with EC 2.4.1.90, N-acetyllactosamine synthase EC 2.4.1.99: sucrose:sucrose fructosyltransferase EC 2.4.1.100: 2,1-fructan:2,1-fructan 1-fructosyltransferase EC 2.4.1.101: α-1,3-mannosyl-glycoprotein 2-β-N-acetylglucosaminyltransferase EC 2.4.1.102: β-1,3-galactosyl-O-glycosyl-glycoprotein β-1,6-N-acetylglucosaminyltransferase EC 2.4.1.103: alizarin 2-β-glucosyltransferase EC 2.4.1.104: o-dihydroxycoumarin 7-O-glucosyltransferase EC 2.4.1.105: vitexin β-glucosyltransferase EC 2.4.1.106: isovitexin β-glucosyltransferase EC 2.4.1.107: deleted, now included with EC 2.4.1.17, glucuronosyltransferase EC 2.4.1.108: deleted, now included with EC 2.4.1.17, glucuronosyltransferase EC 2.4.1.109: dolichyl-phosphate-mannose—protein mannosyltransferase EC 2.4.1.110: tRNA-queuosine β-mannosyltransferase EC 2.4.1.111: coniferyl-alcohol glucosyltransferase EC 2.4.1.112: The protein referred to in this entry is now known to be glycogenin so the entry has been incorporated into EC 2.4.1.186, glycogenin glucosyltransferase EC 2.4.1.113: α-1,4-glucan-protein synthase (ADP-forming) EC 2.4.1.114: 2-coumarate O-β-glucosyltransferase EC 2.4.1.115: anthocyanidin 3-O-glucosyltransferase EC 2.4.1.116: cyanidin 3-O-rutinoside 5-O-glucosyltransferase EC 2.4.1.117: dolichyl-phosphate β-glucosyltransferase EC 2.4.1.118: cytokinin 7-β-glucosyltransferase EC 2.4.1.119: transferred to EC 2.4.99.18, dolichyl-diphosphooligosaccharideprotein glycotransferase EC 2.4.1.120: sinapate 1-glucosyltransferase EC 2.4.1.121: indole-3-acetate β-glucosyltransferase EC 2.4.1.122: N-acetylgalactosaminide β-1,3-galactosyltransferase EC 2.4.1.123: inositol 3-α-galactosyltransferase EC 2.4.1.124: Now EC 2.4.1.87, N-acetyllactosaminide 3-α-galactosyltransferase EC 2.4.1.125: sucrose—1,6-α-glucan 3(6)-α-glucosyltransferase EC 2.4.1.126: hydroxycinnamate 4-β-glucosyltransferase EC 2.4.1.127: monoterpenol β-glucosyltransferase EC 2.4.1.128: scopoletin glucosyltransferase EC 2.4.1.129: peptidoglycan glycosyltransferase EC 2.4.1.130: Now covered by EC 2.4.1.258, EC 2.4.1.259, EC 2.4.1.260 and EC 2.4.1.261 EC 2.4.1.131: GDP-Man:Man3GlcNAc2-PP-dolichol α-1,2-mannosyltransferase EC 2.4.1.132: GDP-Man:Man1GlcNAc2-PP-dolichol α-1,3-mannosyltransferase EC 2.4.1.133: xylosylprotein 4-β-galactosyltransferase EC 2.4.1.134: galactosylxylosylprotein 3-β-galactosyltransferase EC 2.4.1.135: galactosylgalactosylxylosylprotein 3-β-glucuronosyltransferase EC 2.4.1.136: gallate 1-β-glucosyltransferase EC 2.4.1.137: sn-glycerol-3-phosphate 2-α-galactosyltransferase EC 2.4.1.138: mannotetraose 2-α-N-acetylglucosaminyltransferase EC 2.4.1.139: maltose synthase EC 2.4.1.140: alternansucrase EC 2.4.1.141: N-acetylglucosaminyldiphosphodolichol N-acetylglucosaminyltransferase EC 2.4.1.142: chitobiosyldiphosphodolichol β-mannosyltransferase EC 2.4.1.143: α-1,6-mannosyl-glycoprotein 2-β-N-acetylglucosaminyltransferase EC 2.4.1.144: β-1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase EC 2.4.1.145: α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase EC 2.4.1.146: β-1,3-galactosyl-O-glycosyl-glycoprotein β-1,3-N-acetylglucosaminyltransferase EC 2.4.1.147: acetylgalactosaminyl-O-glycosyl-glycoprotein β-1,3-N-acetylglucosaminyltransferase EC 2.4.1.148: acetylgalactosaminyl-O-glycosyl-glycoprotein β-1,6-N-acetylglucosaminyltransferase EC 2.4.1.149: N-acetyllactosaminide β-1,3-N-acetylglucosaminyltransferase EC 2.4.1.150: N-acetyllactosaminide β-1,6-N-acetylglucosaminyltransferase EC 2.4.1.151: now included with EC 2.4.1.87 N-acetyllactosaminide 3-α-galactosyltransferase EC 2.4.1.152: 4-galactosyl-N-acetylglucosaminide 3-α-L-fucosyltransferase EC 2.4.1.153: UDP-N-acetylglucosamine—dolichyl-phosphate N-acetylglucosaminyltransferase EC 2.4.1.154: identical to EC 2.4.1.79, globotriaosylceramide 3-β-N-acetylgalactosaminyltransferase EC 2.4.1.155: α-1,6-mannosyl-glycoprotein 6-β-N-acetylglucosaminyltransferase EC 2.4.1.156: indolylacetyl-myo-inositol galactosyltransferase EC 2.4.1.157: 1,2-diacylglycerol 3-glucosyltransferase, now classified as EC 2.4.1.336, monoglucosyldiacylglycerol synthase, and EC 2.4.1.337, 1,2-diacylglycerol 3-α-glucosyltransferase EC 2.4.1.158: 13-hydroxydocosanoate 13-β-glucosyltransferase EC 2.4.1.159: flavonol-3-O-glucoside L-rhamnosyltransferase EC 2.4.1.160: pyridoxine 5′-O-β-D-glucosyltransferase EC 2.4.1.161: oligosaccharide 4-α-D-glucosyltransferase EC 2.4.1.162: aldose β-D-fructosyltransferase EC 2.4.1.163: now included in EC 2.4.1.149, N-acetyllactosaminide β-1,3-N-acetylglucosaminyltransferase EC 2.4.1.164: now included with EC 2.4.1.150, N-acetyllactosaminide β-1,6-N-acetylglucosaminyltransferase EC 2.4.1.165: N-acetylneuraminylgalactosylglucosylceramide β-1,4-N-acetylgalactosaminyltransferase EC 2.4.1.166: raffinose—raffinose α-galactosyltransferase EC 2.4.1.167: sucrose 6F-α-galactosyltransferase EC 2.4.1.168: xyloglucan 4-glucosyltransferase EC 2.4.1.169: now EC 2.4.2.39, xyloglucan 6-xylosyltransferase EC 2.4.1.170: isoflavone 7-O-glucosyltransferase EC 2.4.1.171: methyl-ONN-azoxymethanol β-D-glucosyltransferase EC 2.4.1.172: salicyl-alcohol β-D-glucosyltransferase EC 2.4.1.173: sterol 3β-glucosyltransferase EC 2.4.1.174: glucuronylgalactosylproteoglycan 4-β-N-acetylgalactosaminyltransferase EC 2.4.1.175: glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-β-N-acetylgalactosaminyltransferase EC 2.4.1.176: gibberellin β-D-glucosyltransferase EC 2.4.1.177: cinnamate β-D-glucosyltransferase EC 2.4.1.178: hydroxymandelonitrile glucosyltransferase EC 2.4.1.179: lactosylceramide β-1,3-galactosyltransferase EC 2.4.1.180: lipopolysaccharide N-acetylmannosaminouronosyltransferase EC 2.4.1.181: hydroxyanthraquinone glucosyltransferase EC 2.4.1.182: lipid-A-disaccharide synthase EC 2.4.1.183: α-1,3-glucan synthase EC 2.4.1.184: galactolipid galactosyltransferase EC 2.4.1.185: flavanone 7-O-β-glucosyltransferase EC 2.4.1.186: glycogenin glucosyltransferase EC 2.4.1.187: N-acetylglucosaminyldiphosphoundecaprenol N-acetyl-β-D-mannosaminyltransferase EC 2.4.1.188: N-acetylglucosaminyldiphosphoundecaprenol glucosyltransferase EC 2.4.1.189: uteolin 7-O-glucuronosyltransferase EC 2.4.1.190: luteolin-7-O-glucuronide 2′′-O-glucuronosyltransferase EC 2.4.1.191: luteolin-7-O-diglucuronide 4′-O-glucuronosyltransferase EC 2.4.1.192: nuatigenin 3β-glucosyltransferase EC 2.4.1.193: sarsapogenin 3β-glucosyltransferase EC 2.4.1.194: 4-hydroxybenzoate 4-O-β-D-glucosyltransferase EC 2.4.1.195: N-hydroxythioamide S-β-glucosyltransferase EC 2.4.1.196: nicotinate glucosyltransferase EC 2.4.1.197: high-mannose-oligosaccharide β-1,4-N-acetylglucosaminyltransferase EC 2.4.1.198: phosphatidylinositol N-acetylglucosaminyltransferase EC 2.4.1.199: β-mannosylphosphodecaprenol—mannooligosaccharide 6-mannosyltransferase EC 2.4.1.200: now EC 4.2.2.17, inulin fructotransferase (DFA-I-forming) EC 2.4.1.201: α-1,6-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase EC 2.4.1.202: 2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one 2-D-glucosyltransferase EC 2.4.1.203: trans-zeatin O-β-D-glucosyltransferase EC 2.4.1.204: now EC 2.4.2.40, zeatin O-β-D-xylosyltransferase EC 2.4.1.205: galactogen 6β-galactosyltransferase EC 2.4.1.206: lactosylceramide 1,3-N-acetyl-β-D-glucosaminyltransferase EC 2.4.1.207: xyloglucan:xyloglucosyl transferase EC 2.4.1.208: diglucosyl diacylglycerol synthase (1,2-linking) EC 2.4.1.209: cis-p-coumarate glucosyltransferase EC 2.4.1.210: limonoid glucosyltransferase EC 2.4.1.211: 1,3-β-galactosyl-N-acetylhexosamine phosphorylase EC 2.4.1.212: hyaluronan synthase EC 2.4.1.213: glucosylglycerol-phosphate synthase EC 2.4.1.214: glycoprotein 3-α-L-fucosyltransferase EC 2.4.1.215: cis-zeatin O-β-D-glucosyltransferase EC 2.4.1.216: trehalose 6-phosphate phosphorylase EC 2.4.1.217: mannosyl-3-phosphoglycerate synthase EC 2.4.1.218: hydroquinone glucosyltransferase EC 2.4.1.219: vomilenine glucosyltransferase EC 2.4.1.220: indoxyl-UDPG glucosyltransferase EC 2.4.1.221: peptide-O-fucosyltransferase EC 2.4.1.222: O-fucosylpeptide 3-β-N-acetylglucosaminyltransferase EC 2.4.1.223: glucuronosyl-galactosyl-proteoglycan 4-α-N-acetylglucosaminyltransferase EC 2.4.1.224: glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-α-N-acetylglucosaminyltransferase EC 2.4.1.225: N-acetylglucosaminyl-proteoglycan 4-β-glucuronosyltransferase EC 2.4.1.226: N-acetylgalactosaminyl-proteoglycan 3-β-glucuronosyltransferase EC 2.4.1.227: undecaprenyldiphospho-muramoylpentapeptide β-N-acetylglucosaminyltransferase EC 2.4.1.228: lactosylceramide 4-α-galactosyltransferase EC 2.4.1.229: [Skp1-protein]-hydroxyproline N-acetylglucosaminyltransferase EC 2.4.1.230: kojibiose phosphorylase EC 2.4.1.231: α,α-trehalose phosphorylase (configuration-retaining) EC 2.4.1.232: initiation-specific α-1,6-mannosyltransferase EC 2.4.1.233: deleted: identical to EC 2.4.1.115, anthocyanidin 3-O-glucosyltransferase EC 2.4.1.234: kaempferol 3-O-galactosyltransferase EC 2.4.1.235: deleted: identical to EC 2.4.1.116, cyanidin 3-O-rutinoside 5-O-glucosyltransferase EC 2.4.1.236: flavanone 7-O-glucoside 2′′-O-β-L-rhamnosyltransferase EC 2.4.1.237: flavonol 7-O-β-glucosyltransferase EC 2.4.1.238: delphinidin 3,5-di-O-glucoside 3′-O-glucosyltransferase EC 2.4.1.239: flavonol-3-O-glucoside glucosyltransferase EC 2.4.1.240: flavonol-3-O-glycoside glucosyltransferase EC 2.4.1.241: flavonol-3-O-glycoside glucosyltransferase EC 2.4.1.242: NDP-glucose—starch glucosyltransferase EC 2.4.1.243: 6G-fructosyltransferase EC 2.4.1.244: N-acetyl-β-glucosaminyl-glycoprotein 4-β-N-acetylgalactosaminyltransferase EC 2.4.1.245: α,α-trehalose synthase EC 2.4.1.246: mannosylfructose-phosphate synthase EC 2.4.1.247: β-D-galactosyl-(1→4)-L-rhamnose phosphorylase EC 2.4.1.248: cycloisomaltooligosaccharide glucanotransferase EC 2.4.1.249: delphinidin 3′,5′-O-glucosyltransferase EC 2.4.1.250: D-inositol-3-phosphate glycosyltransferase EC 2.4.1.251: GlcA-β-(1→2)-D-Man-α-(1→3)-D-Glc-β-(1→4)-D-Glc-α-1-diphospho-ditrans,octacis-undecaprenol 4-β-mannosyltransferase EC 2.4.1.252: GDP-mannose:cellobiosyl-diphosphopolyprenol α-mannosyltransferase EC 2.4.1.253: baicalein 7-O-glucuronosyltransferase EC 2.4.1.254: cyanidin-3-O-glucoside 2′′-O-glucuronosyltransferase EC 2.4.1.255: protein O-GlcNAc transferase EC 2.4.1.256: dolichyl-P-Glc:Glc2Man9GlcNAc2-PP-dolichol α-1,2-glucosyltransferase EC 2.4.1.257: GDP-Man:Man2GlcNAc2-PP-dolichol α-1,6-mannosyltransferase EC 2.4.1.258: dolichyl-P-Man:Man5GlcNAc2-PP-dolichol α-1,3-mannosyltransferase EC 2.4.1.259: dolichyl-P-Man:Man6GlcNAc2-PP-dolichol α-1,2-mannosyltransferase EC 2.4.1.260: dolichyl-P-Man:Man7GlcNAc2-PP-dolichol α-1,6-mannosyltransferase EC 2.4.1.261: dolichyl-P-Man:Man8GlcNAc2-PP-dolichol α-1,2-mannosyltransferase EC 2.4.1.262: soyasapogenol glucuronosyltransferase EC 2.4.1.263: abscisate β-glucosyltransferase EC 2.4.1.264: D-Man-α-(1→3)-D-Glc-β-(1→4)-DD-Glc-α-1-diphosphoundecaprenol 2-β-glucuronosyltransferase EC 2.4.1.265: olichyl-P-Glc:Glc1Man9GlcNAc2-PP-dolichol α-1,3-glucosyltransferase EC 2.4.1.266: glucosyl-3-phosphoglycerate synthase EC 2.4.1.267: dolichyl-P-Glc:Man9GlcNAc2-PP-dolichol α-1,3-glucosyltransferase EC 2.4.1.268: glucosylglycerate synthase EC 2.4.1.269: mannosylglycerate synthase EC 2.4.1.270: mannosylglucosyl-3-phosphoglycerate synthase EC 2.4.1.271: crocetin glucosyltransferase EC 2.4.1.272: soyasapogenol B glucuronide galactosyltransferase EC 2.4.1.273: soyasaponin III rhamnosyltransferase EC 2.4.1.274: glucosylceramide β-1,4-galactosyltransferase EC 2.4.1.275: neolactotriaosylceramide β-1,4-galactosyltransferase EC 2.4.1.276: zeaxanthin glucosyltransferase EC 2.4.1.277: glycosyltransferase DesVII EC 2.4.1.278: desosaminyl transferase EryCIII EC 2.4.1.279: nigerose phosphorylase EC 2.4.1.280: N,N′-diacetylchitobiose phosphorylase EC 2.4.1.281: 4-O-β-D-mannosyl-D-glucose phosphorylase EC 2.4.1.282: 3-O-α-D-glucosyl-L-rhamnose phosphorylase EC 2.4.1.283: 2-deoxystreptamine N-acetyl-D-glucosaminyltransferase EC 2.4.1.284: 2-deoxystreptamine glucosyltransferase EC 2.4.1.285: UDP-GlcNAc:ribostamycin N-acetylglucosaminyltransferase EC 2.4.1.286: chalcone 4′-O-glucosyltransferase EC 2.4.1.287: rhamnopyranosyl-N-acetylglucosaminyl-diphospho-decaprenol β-1,4/1,5-galactofuranosyltransferase EC 2.4.1.288: galactofuranosylgalactofuranosylrhamnosyl-N-acetylglucosaminyl-diphospho-decaprenol β-1,5/1,6-galactofuranosyltransferase EC 2.4.1.289: N-acetylglucosaminyl-diphospho-decaprenol L-rhamnosyltransferase EC 2.4.1.290: N,N′-diacetylbacillosaminyl-diphospho-undecaprenol α-1,3-N-acetylgalactosaminyltransferase EC 2.4.1.291: N-acetylgalactosamine-N,N′-diacetylbacillosaminyl-diphospho-undecaprenol 4-α-N-acetylgalactosaminyltransferase EC 2.4.1.292: GalNAc-α-(1→4)-GalNAc-α-(1→3)-diNAcBac-PP-undecaprenol α-1,4-N-acetyl-D-galactosaminyltransferase EC 2.4.1.293: GalNAc5-diNAcBac-PP-undecaprenol β-1,3-glucosyltransferase EC 2.4.1.294: cyanidin 3-O-galactosyltransferase EC 2.4.1.295: anthocyanin 3-O-sambubioside 5-O-glucosyltransferase EC 2.4.1.296: anthocyanidin 3-O-coumaroylrutinoside 5-O-glucosyltransferase EC 2.4.1.297: anthocyanidin 3-O-glucoside 2′′-O-glucosyltransferase EC 2.4.1.298: anthocyanidin 3-O-glucoside 5-O-glucosyltransferase EC 2.4.1.299: cyanidin 3-O-glucoside 5-O-glucosyltransferase (acyl-glucose) EC 2.4.1.300: cyanidin 3-O-glucoside 7-O-glucosyltransferase (acyl-glucose) EC 2.4.1.301: 2′-deamino-2′-hydroxyneamine 1-α-D-kanosaminyltransferase EC 2.4.1.302: L-demethylnoviosyl transferase EC 2.4.1.303: UDP-Gal:α-D-GlcNAc-diphosphoundecaprenol β-1,3-galactosyltransferase EC 2.4.1.304: UDP-Gal:α-D-GlcNAc-diphosphoundecaprenol β-1,4-galactosyltransferase EC 2.4.1.305: UDP-Glc:α-D-GlcNAc-glucosaminyl-diphosphoundecaprenol β-1,3-glucosyltransferase EC 2.4.1.306: UDP-GalNAc:α-D-GalNAc-diphosphoundecaprenol α-1,3-N-acetylgalactosaminyltransferase EC 2.4.1.307: UDP-Gal:α-D-GalNAc-1,3-α-D-GalNAc-diphosphoundecaprenol β-1,3-galactosyltransferase. Now included in EC 2.4.1.122, N-acetylgalactosaminide β-1,3-galactosyltransferase EC 2.4.1.308: GDP-Fuc:β-D-Gal-1,3-α-D-GalNAc-1,3-α-GalNAc-diphosphoundecaprenol α-1,2-fucosyltransferase EC 2.4.1.309: UDP-Gal:α-L-Fuc-1,2-β-Gal-1,3-α-GalNAc-1,3-α-GalNAc-diphosphoundecaprenol α-1,3-galactosyltransferase EC 2.4.1.310: vancomycin aglycone glucosyltransferase EC 2.4.1.311: chloroorienticin B synthase EC 2.4.1.312: protein O-mannose β-1,4-N-acetylglucosaminyltransferase EC 2.4.1.313: protein O-mannose β-1,3-N-acetylgalactosaminyltransferase EC 2.4.1.314: ginsenoside Rd glucosyltransferase EC 2.4.1.315: diglucosyl diacylglycerol synthase (1,6-linking) EC 2.4.1.316: tylactone mycaminosyltransferase EC 2.4.1.317: O-mycaminosyltylonolide 6-deoxyallosyltransferase EC 2.4.1.318: demethyllactenocin mycarosyltransferase EC 2.4.1.319: β-1,4-mannooligosaccharide phosphorylase EC 2.4.1.320: 1,4-β-mannosyl-N-acetylglucosamine phosphorylase EC 2.4.1.321: cellobionic acid phosphorylase EC 2.4.1.322: devancosaminyl-vancomycin vancosaminetransferase EC 2.4.1.323: 7-deoxyloganetic acid glucosyltransferase EC 2.4.1.324: 7-deoxyloganetin glucosyltransferase EC 2.4.1.325: TDP-N-acetylfucosamine:lipid II N-acetylfucosaminyltransferase EC 2.4.1.326: aklavinone 7-L-rhodosaminyltransferase EC 2.4.1.327: aclacinomycin-T 2-deoxy-L-fucose transferase EC 2.4.1.328: erythronolide mycarosyltransferase EC 2.4.1.329: sucrose 6F-phosphate phosphorylase EC 2.4.1.330: β-D-glucosyl crocetin β-1,6-glucosyltransferase EC 2.4.1.331: 8-demethyltetracenomycin C L-rhamnosyltransferase EC 2.4.1.332: 1,2-α-glucosylglycerol phosphorylase EC 2.4.1.333: 1,2-β-oligoglucan phosphorylase EC 2.4.1.334: 1,3-α-oligoglucan phosphorylase EC 2.4.1.335: dolichyl N-acetyl-α-D-glucosaminyl phosphate 3-β-D-2,3-diacetamido-2,3-dideoxy-β-D-glucuronosyltransferase EC 2.4.1.336: monoglucosyldiacylglycerol synthase EC 2.4.1.337: 1,2-diacylglycerol 3-α-glucosyltransferase EC 2.4.1.338: validoxylamine A glucosyltransferase EC 2.4.1.339: β-1,2-mannobiose phosphorylase EC 2.4.1.340: 1,2-β-oligomannan phosphorylase EC 2.4.1.341: α-1,2-colitosyltransferase EC 2.4.1.342: α-maltose-1-phosphate synthase EC 2.4.1.343: UDP-Gal:α-D-GlcNAc-diphosphoundecaprenol α-1,3-galactosyltransferase EC 2.4.1.344: type 2 galactoside α-(1,2)-fucosyltransferase EC 2.4.1.345: phosphatidyl-myo-inositol α-mannosyltransferase EC 2.4.1.346: phosphatidyl-myo-inositol dimannoside synthase EC 2.4.1.347: α,α-trehalose-phosphate synthase (ADP-forming) EC 2.4.1.348: N-acetyl-α-D-glucosaminyl-diphospho-ditrans,octacis-undecaprenol 3-α-mannosyltransferase EC 2.4.1.349: mannosyl-N-acetyl-α-D-glucosaminyl-diphospho-ditrans,octacis-undecaprenol 3-α-mannosyltransferase EC 2.4.1.350: mogroside IE synthase EC 2.4.1.351: rhamnogalacturonan I rhamnosyltransferase EC 2.4.1.352: glucosylglycerate phosphorylase EC 2.4.1.353: sordaricin 6-deoxyaltrosyltransferase EC 2.4.1.354: (R)-mandelonitrile β-glucosyltransferase EC 2.4.1.355: poly(ribitol-phosphate) β-N-acetylglucosaminyltransferase EC 2.4.1.356: glucosyl-dolichyl phosphate glucuronosyltransferase EC 2.4.1.357: phlorizin synthase EC 2.4.1.358: acylphloroglucinol glucosyltransferase EC 2.4.1.359: glucosylglycerol phosphorylase (configuration-retaining) EC 2.4.1.360: 2-hydroxyflavanone C-glucosyltransferase EC 2.4.1.361: GDP-mannose:di-myo-inositol-1,3′-phosphate β-1,2-mannosyltransferase EC 2.4.1.362: α-(1→3) branching sucrase EC 2.4.1.363: ginsenoside 20-O-glucosyltransferase EC 2.4.1.364: protopanaxadiol-type ginsenoside 3-O-glucosyltransferase EC 2.4.1.365: protopanaxadiol-type ginsenoside-3-O-glucoside 2′′-O-glucosyltransferase EC 2.4.1.366: ginsenoside F1 6-O-glucosyltransferase EC 2.4.1.367: ginsenoside 6-O-glucosyltransferase EC 2.4.1.368: oleanolate 3-O-glucosyltransferase EC 2.4.1.369: enterobactin C-glucosyltransferase EC 2.4.1.370: inositol phosphorylceramide mannosyltransferase EC 2.4.1.371: polymannosyl GlcNAc-diphospho-ditrans,octacis-undecaprenol 2,3-α-mannosylpolymerase EC 2.4.1.372: mutansucrase EC 2.4.1.373: α-(1→2) branching sucrase EC 2.4.1.374: β-1,2-mannooligosaccharide synthase EC 2.4.1.375: rhamnogalacturonan I galactosyltransferase EC 2.4.1.376: EGF-domain serine glucosyltransferase EC 2.4.1.377: dTDP-Rha:α-D-Gal-diphosphoundecaprenol α-1,3-rhamnosyltransferase EC 2.4.1.378: GDP-mannose:α-L-Rha-(1→3)-α-D-Gal-PP-Und α-1,4-mannosyltransferase EC 2.4.1.379: GDP-Man:α-D-Gal-diphosphoundecaprenol α-1,3-mannosyltransferase EC 2.4.1.380: GDP-Man:α-D-Man-(1→3)-α-D-Gal diphosphoundecaprenol α-1,2-mannosyltransferase EC 2.4.1.381: dTDP-Rha:α-D-Man-(1→3)-α-D-Gal diphosphoundecaprenol α-1,2-rhamnosyltransferase EC 2.4.1.382: CDP-abequose:α-L-Rha2OAc-(1→2)-α-D-Man-(1→2)-α-D-Man-(1→3)-α-D-Gal-PP-Und α-1,3-abequosyltransferase EC 2.4.1.383: GDP-Man:α-L-Rha-(1→3)-α-D-Gal-PP-Und β-1,4-mannosyltransferase EC 2.4.1.384: NDP-glycosyltransferase
When the protein is labelled with carbon-13 and nitrogen-15 it is possible to record triple resonance experiments that transfer magnetisation over the peptide bond, and thus connect different spin systems through bonds. This is usually done using some of the following experiments, HNCO, HN(CA)CO}, HNCA, HN(CO)CA, HNCACB and CBCA(CO)NH. All six experiments consist of a 1H-15N plane (similar to a HSQC spectrum) expanded with a carbon dimension. In the HN(CA)CO, each HN plane contains the peaks from the carbonyl carbon from its residue as well the preceding one in the sequence. The HNCO contains the carbonyl carbon chemical shift from only the preceding residue, but is much more sensitive than HN(CA)CO. These experiments allow each 1H-15N peak to be linked to the preceding carbonyl carbon, and sequential assignment can then be undertaken by matching the shifts of each spin system's own and previous carbons. The HNCA and HN(CO)CA works similarly, just with the alpha carbons (Cα) rather than the carbonyls, and the HNCACB and the CBCA(CO)NH contains both the alpha carbon and the beta carbon (Cβ). Usually several of these experiments are required to resolve overlap in the carbon dimension. This procedure is usually less ambiguous than the NOESY-based method since it is based on through bond transfer. In the NOESY-based methods, additional peaks corresponding to atoms that are close in space but that do not belong to sequential residues will appear, confusing the assignment process.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.